TheraRadar
← Back
Data updated: Jun 28, 2026

CISEN

Generics

CISEN is a generic drug manufacturer focused on Infectious Disease, Cardiovascular, Gastroenterology.

2020
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

CISEN's Key Drugs

CISEN's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

CISEN's Recent FDA Approvals

New NDA/BLA approvals for CISEN over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

CISEN's Therapeutic Areas

CISEN's approved drugs and pipeline span 3 therapeutic areas, led by Infectious Disease and Cardiovascular. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 33%
1 drugs
Cardiovascular 33%
1 drugs
Gastroenterology 33%
1 drugs

CISEN's Top Competitors

CISEN's closest competitors by therapeutic-area and drug-target overlap include APOTHECON, WAYLIS THERAP, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

CISEN Pipeline Snapshot

Active clinical trials for CISEN across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Infectious Disease pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling